Sinovant Sciences Announces Approval of Derazantinib’s Clinical Trial Application by the China National Medical Products Administration

ArQule, Inc.’s (Nasdaq: ARQL) partner, Sinovant Sciences, announced that its Clinical Trial Application (CTA) for derazantinib …
(Orginal – Story lesen…)

This website stores some user agent data. These data are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to opt-out of any future tracking, a cookie will be set up in your browser to remember this choice for one year. I Agree, Deny
780